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Abstract  
Improved clinical care for Bipolar Disorder (BD) relies on the identification of diagnostic markers that 
can reliably detect disease-related signals in clinically heterogeneous populations. At the very least, 
diagnostic markers should be able to differentiate patients with BD from healthy individuals and 
from individuals at familial risk for BD who either remain well or develop other psychopathology , 
most commonly Major Depressive Disorder (MDD). These issues are particularly pertinent to the 
development of translational applications of neuroimaging as they represent challenges for which 
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clinical observation alone is insufficient. We therefore applied pattern classification to task-based 
functional magnetic resonance imaging (fMRI) data of the n-back working memory task, to test their 
predictive value in differentiating patients with BD (n=30) from healthy individuals (n=30) and from 
patients’ relatives who were either diagnosed with MDD (n=30) or were free of any personal lifetime 
history of psychopathology (n=30). Diagnostic stability in these groups was confirmed with 4-year 
prospective follow-up. Task-based activation patterns from the fMRI data were analyzed with 
Gaussian Process Classifiers (GPC), a machine learning approach to detecting multivariate patterns in 
neuroimaging datasets. Consistent significant classification results were only obtained using data 
from the 3-back versus 0-back contrast.  Using contrast, patients with BD were correctly classified 
compared to unrelated healthy individuals with an accuracy of 83.5%, sensitivity of 84.6% and 
specificity of 92.3%. Classification accuracy, sensitivity and specificity when comparing patients with 
BD to their relatives with MDD, were respectively 73.1%, 53.9% and 94.5%. Classification accuracy, 
sensitivity and specificity when comparing patients with BD to their healthy relatives were 
respectively 81.8%, 72.7% and 90.9%.  We show that significant individual classification can be 
achieved using whole brain pattern analysis of task-based working memory fMRI data. The high 
accuracy and specificity achieved by all three classifiers suggest that multivariate pattern recognition 
analyses can aid clinicians in the clinical care of BD in situations of true clinical uncertainty regarding 
the diagnosis and prognosis.  
 
 
 
 
 
INTRODUCTION  
 
Bipolar disorder (BD) is an affective disorder that ranks amongst the leading causes of disability 
worldwide across all age groups (World Health Organization, 2008). This motivates efforts to 
characterize valid and reliable biological markers of disease expression in order to facilitate early 
identification and novel treatment discovery. 
 
Magnetic resonance imaging (MRI) has been extensively used to investigate the neural correlates of 
disease expression in BD. Structural MRI (sMRI) studies have demonstrated that BD is associated 
with reductions in whole brain and regional gray matter volumes (Hallahan et al., 2011; Kempton et 
al., 2011; Fears et al., 2014). Functional MRI (fMRI) studies have provided further information in 
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terms of changes in regional blood-oxygen-level-dependent (BOLD) signal, most commonly in the 
domains of affect processing and executive control,  where both genetically-derived and disease-
related deficits have been reported (Glahn et al., 2010;  Fears et al., 2014).  The common network 
for affect processing notably involves the amygdala (AMG), ventral striatum and putamen and the 
ventral prefrontal (VPFC), ventral anterior cingulate (ACC) and insular cortices (Lindquist et al., 
2012). The common network supporting executive control functions includes dorsal striatal 
structures as well as the dorsolateral prefrontal (DLPFC), dorsal ACC, and parietal (PAR) cortices 
(Niendam et al., 2012). In patients with BD, exaggerated activation during affective and executive 
tasks has been consistently observed in the AMG, insula, and ventral ACC coupled with reduced PFC 
engagement (Chen at al., 2011; Cusi et al., 2012; Delvecchio et al., 2012; Fusar-Poli et al., 2012; Jogia 
et al., 2012; Cremaschi et al., 2013; Dima et al., 2013).  These observations have improved the 
characterization of the biological underpinnings of BD but have had limited clinical utility as they are 
based on group-level inferences that cannot be readily applied to the categorization of single 
individuals.  
 
Advances in machine learning techniques, a field of artificial intelligence, represent a major 
development that could lead to clinical useful neuroimaging applications in psychiatry.  Multivariate 
pattern recognition is a particular type of machine learning concerned with the discovery of 
regularities in data through the use of computer algorithms (Vapnik 1995). Frequently used machine 
learning approaches are support vector machines (SVM) and Gaussian Process Classifiers (GPC) 
(Figure 1). Our group and others have shown that the application of multivariate pattern recognition 
analyses can reliably classify patients with BD from healthy individuals (Rocha-Rego et al., 2014; 
Mwangi et al., 2014; Schnack et al., 2014) and from patients with schizophrenia (Schnack et al., 
2014) or Major Depressive Disorder (MDD) (Grotegerd et al., 2013; Grotegerd et al., 2014) with an 
accuracy of approximately 70-80%.   
 
It can be argued however, that neuroimaging may be able to make a unique contribution in 
situations where clinical assessment and observation are not sufficient for diagnosis and prognosis. 
For clinicians, one of the greatest challenges lies in the differential diagnosis of BD from MDD. 
Although mania is the diagnostic hallmark of BD, in the majority of patients the disorder first 
presents with depressive symptoms (Forty et al., 2009). Even after disease onset, depressive 
symptoms dominate and contribute to morbidity and psychosocial disability (Judd et al., 2002). A 
substantial body of research has focused on identifying phenomenological features that could 
differentiate MDD from BD depression; the weight of evidence suggests that reliable and accurate 
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differentiation at the level of the individual patient is beyond the resolution of even rigorous and 
detailed clinical assessment (Mitchell et al., 2008), particularly amongst those with a family history 
of BD (Mitchell et al., 2011). Consequently, many patients are misdiagnosed and treated as having 
MDD either because they present with depression at illness onset or because they generally under-
report manic symptoms. This has important treatment implications as antidepressant treatment in 
BD may exaggerate mood instability (El-Mallakh et al., 2015). A further challenge lies in predicting 
the outcome of asymptomatic individuals with a family history of BD. As a group, these individuals 
are a higher risk than the general population for developing BD (Duffy et al., 2015; Fullerton et al., 
2015).  
 
Therefore the aim of the current study was to test whether neuroimaging can indeed assist clinicians 
when faced with true clinical uncertainty in situations where clinical acumen and observation are 
insufficient. We tackle two challenges; one focuses on the differential diagnosis of BD from MDD in 
the presence of family history of BD in the MDD patients. The other on the correct identification of 
individuals who have remained well but would be conventionally considered “at risk” based on 
having a first-degree relative with BD. We therefore test the hypothesis that GPCs of task-based 
fMRI data during the n-back working memory task can identify patterns of neural function that will 
prove useful in differentiating patients with BD from healthy unrelated individuals, and individuals at 
familial risk for BD who have either developed MDD or remained free of psychopathology.  We focus 
on the functional neuroanatomy of the n-back task because it has been shown to be robust to 
variations in the paradigms used, scanner types and acquisition sequences (Owen et al., 2005; Dima 
et al., 2014) and has been reliably used to elicit disease-related abnormalities in patients with BD 
and their relatives (Fusar-Poli et al., 2012; Cremaschi et al., 2013). 
 
METHODS 
 
The study sample comprised 120 demographically matched participants consisting of 30 patients 
with BD-type I, 30 of their first-degree relatives diagnosed with MDD, 30 psychiatrically healthy first-
degree relatives and 30 unrelated healthy controls (Table 1).  Participants were drawn from with the 
VIBES study sample (Frangou 2009; Kempton et al., 2009a,b; Walterfang et al., 2009; Takahashi et 
al., 2010; Forcada et al., 2011; Lelli-Chiesa et al., 2011; Perrier et al., 2011; Pompei et al., 2011a,b; 
Ruberto et al., 2011; Jogia et al., 2011; Jogia et al., 2012a,b; Dima et al., 2013; Rocha-Rego et al., 
2014; Delvecchio et al., 2015).  Participants with BD or MDD fulfilled the respective diagnostic 
criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, revised 
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(DSM-IV) (APA, 1994). Healthy relatives had no lifetime history of any major psychiatric disorder. 
Healthy unrelated controls had no family history or personal lifetime history of any major psychiatric 
disorder. All participants were free of any medical comorbidity and had no lifetime history of 
substance dependence or substance abuse in the six months leading to their brain scan. The 
diagnostic status of all participants was assessed using the Structured Clinical Interview for DSM-IV 
for Axis I diagnoses (First et al., 2002a, b). Patients with BD and their relatives with MDD did not 
differ in the age of onset of their respective diagnosis.  The diagnostic stability of patients with BD, 
their MDD and healthy relatives was confirmed through annual interview over a 4-year period 
following their brain scan. On the day of scanning, all participants were assessed using the Hamilton 
Depression Rating Scale (HDRS) (Hamilton, 1960), the Young Mania Rating Scale (YMRS) (Young et 
al., 1978), the Brief Psychiatric Rating Scale (BPRS) (Lukoff et al., 1986) and the Wechsler Adult 
Intelligence Scale 3rd Edition (Wechsler, 1997). To ensure patients with BD and relatives with MDD 
were in remission their psychopathology was assessed weekly over period of 1 month leading to 
their scan and at each assessment patients’ scored below 7 in the HDRS and YMRS.  Although the 
level of symptomatology was very low, patients with BD were more symptomatic than all other 
groups (p<0.001).  The BPRS, HDRS and YMRS scores were highly correlated (all r > 0.78, all p< 
0.001).BD patients were medicated at the time of scanning with atypical antipsychotics (n=21), 
antiepileptics (n=8), lithium (n=14), as monotherapy (n=18) or combination therapy (n=12). Three 
relatives with MDD were on selective serotonin re-uptake inhibitors. All medicated participants had 
remained on the same type and dose of medication for a minimum of 6 months prior to scanning.   
Informed consent was obtained from all participants. The study was approved by the institutional 
ethics review board. 
 
 
Working Memory Functional Imaging Task  
The n-back task was employed in a block design incorporating alternating experimental and 
sensorimotor control conditions. A series of letters in yellow font were displayed on a blue screen 
for two seconds each. Participants were instructed to indicate by a button press whether the letter 
currently displayed matched the letter from the preceding n trials. In the sensorimotor control (0-
back) the letter “X” was the designated target. In the experimental conditions (1, 2, 3-back) the 
target letter was defined as any letter that was identical to the one presented in the preceding one, 
two, or three trials. There were 18 epochs in all, each lasting 30 seconds, comprising 14 letters with 
a ratio of target to non-target letters ranging from 2:12 to 4:10 per epoch. The entire experiment 
lasted 9 minutes and included a total of 49 target and 203 non-target stimuli. To avoid any 
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systematic order effects the conditions were pseudo-randomised. Performance was evaluated in 
terms of reaction time to target letters and accuracy (% correct responses).The task was explained to 
participants prior to scanning but there was no training. 
 
Image acquisition 
Gradient echo planar magnetic resonance (MR) images were acquired using a 1.5-Tesla GE Neuro-
optimised Signa MR system (General Electric, Milwaukee, WI, USA) fitted with 40 mT/m highspeed 
gradients. Foam padding and a forehead strap were used to limit head motion. A quadrature 
birdcage head coil was used for radio frequency (RF) transmission and reception. A total of 180 T2*-
weighted MR brain volumes depicting BOLD contrast were acquired at each of 36 near-axial planes 
parallel to the inter-commissural (AC-PC) plane; repetition time (TR) = 3000ms, echo time (TE) = 
40ms, slice thickness = 3mm, voxel dimensions = 3.75 x 3.75 x 3.30mm, interslice gap = 0.3mm, 
matrix size = 64 * 64, flip angle=90°. Prior to each acquisition sequence, four dummy data acquisition 
scans were performed to allow the scanner to reach a steady state in T1 contrast. During the same 
session, a high-resolution T1-weighted structural image was acquired in the axial plane (inversion 
recovery prepared, spoiled gradient-echo sequence; TR = 18ms, TE = 5.1 ms, TI = 450 ms, slice 
thickness = 1.5 mm, voxel dimensions = 0.9375 × 0.9375 x 1.5 mm, matrix size 256 * 192, field of 
view = 240 x 180 mm, flip angle = 20°, number of excitations = 1) for subsequent co-registration. 
 
Image Processing 
Conventional fMRI analyses were implemented using Statistical Parametric Mapping (SPM8) 
(www.fil.ion.ucl.ac.uk/spm/software/spm8/). fMRI images were realigned, normalized and 
smoothed using an 8 mm full-width-half-maximum Gaussian kernel. To ensure data quality, task 
registration parameters were extracted and were used to identify participants with excessive 
interscan motion (defined as >4 mm translation, >4° rotation) and to conduct group comparisons. No 
subjects were excluded and there were no significant group differences in motion. The smoothed 
single-participant images were analysed via multiple regressions using the linear convolution model, 
with vectors of onset representing the memory load conditions (1, 2, and 3 back) and the 0-back 
condition as sensorimotor control. Six movement parameters were also entered as nuisance 
covariates. Serial correlations were removed using an AR(1) model. A high pass filter (128s) was 
applied to remove low-frequency noise. Contrast images of each memory load condition (1-, 2-, 3- 
back) versus 0-back were produced for each participant. At the individual subject level, a standard 
general linear modelling (GLM) approach was used to obtain estimates of the response size (beta) in 
each the memory load condition against the 0-back control condition. 
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Conventional fMRI Analysis  
We examined the effect of group (patients with BD, MDD relatives, healthy relatives and unrelated 
healthy controls) on BOLD signal using a standard general linear modelling (GLM) in SPM8 separately 
for each memory load condition (1-, 2-, 3- back) against the 0-back control. We examined each 
condition separately, instead of modelling activation changes with increasing load. This is because it 
has long been known that cortical loci, particularly in prefrontal regions, show non-linear changes in 
activation with increasing memory load (Callicott et al., 1999) which could increase voxel level 
variability. Suprathreshold clusters were identified using family wise error (FWE) voxel-wise 
correction of p<0.05. Stereotactic coordinates were converted from MNI spatial array to that of 
Talairach and Tournoux (www.mrc-cbu.cam.ac.uk/Imaging/mnispace.html) and corresponding 
anatomical and Brodmann area (BA) labels were identified with The Talairach Daemon Client 
(www.talairach.org). Measures of brain activation (weighted parameter estimates) from each 
subject were extracted using the MarsBaR toolbox (marsbar.sourceforge.net) from regions of 
interest (ROIs) defined on the basis of the whole brain analysis as 5 mm radius spheres at peak 
height coordinates within each suprathreshold cluster. These measures were also used to examine 
the role of potentially confounding variables of age, IQ, age of onset, task performance and 
medication. Although we report uncorrected P values, due to the large number of correlations 
undertaken the level of significant inference was set at a conservative P vale of 0.005.  
 
Multivariate pattern classification 
Probability of group membership was determined using Gaussian Process Classifiers (GPCs) 
implemented in the Pattern Recognition for Neuroimaging Toolbox (PRoNTo) 
(www.mlnl.cs.ucl.ac.uk/pronto/) using whole-brain individual beta maps/GLM coefficients for the 
contrasts of 1-back, 2-back and 3-back versus 0-back. Technical descriptions of GPC inference have 
been presented elsewhere (Schrouff et al. 2013). Briefly, the classifier is first trained to determine a 
predictive distribution that best distinguishes between two groups (e.g., case and controls); any 
parameters controlling the behaviour of this distribution are computed by maximizing the logarithm 
of the marginal likelihood on the training data only. Then in the test phase, the classifier predicts the 
group membership of a previously unseen example. This is achieved by integrating over the 
predictive distribution for the test case and passing the output through a sigmoidal function, 
resulting in predictive probabilities scaled between 0 and 1 which precisely quantify the predictive 
uncertainty of the classifier for the test case.   
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We focus on the usefulness of fMRI data derived from the n-back task in differentiating patients with 
BD from (a) healthy individuals, (b) their relatives with MDD, and (c) from their psychiatrically 
healthy relatives. Each classifiers was trained a leave-two-out cross-validation. For each cross-
validation iteration, a matched pair of subjects from each group was excluded first and then the data 
were partitioned into training and test sets. For each trial, we thresholded the probabilistic 
predictions at 0.5 to convert the probabilistic predictions to class labels allowing the sensitivity and 
specificity of classification to be computed over all trials (Rasmussen and Williams, 2006). Statistical 
significance of each classifier was determined by permutation testing, as described previously 
(Marquand et al., 2010). Briefly, permutation testing was performed by repeatedly retraining the 
classifier after permuting the class labels (1000 permutations). A P-value for classification accuracy 
was computed by counting the number of permutations for which the permuted accuracy was equal 
or greater than the true accuracy (obtained with non-permuted labels), then dividing by 1000. In 
addition for each classifier, Pearson correlation analyses were carried out between GPC predictive 
probability and total BPRS scores, age, IQ, task performance, age of onset and medication dose. 
As a secondary outcome we generated an unthresholded GPC weight map for each classifier. As GPC 
classifiers are multivariate, these discrimination maps do not describe focal activation effects but 
instead they represent the spatially distributed pattern of coefficients that quantify the contribution 
of each voxel to the classifier’s decision function.  We then estimated the positive (PPV) and negative 
(NPV) predictive value of each classifier.  
 
RESULTS 
Conventional fMRI Analysis 
There were no group differences in the 1-back or 2-back versus 0-back contrasts. In the 3-back 
versus 0-back contrast a main effect of group was found (p=0.05 FWE voxel level corrected) in the 
middle frontal gyrus (BA10) (x=36 y=58 z=0, F score= 6.64, cluster size 240), the superior temporal 
gyrus (BA22) (x=58 y=-44 z=12, F score=6.54, cluster size 169) and the posterior cingulate cortex 
(BA30) (x=-28 y=-68 z=8, F score= 6.97, cluster size 76). Patients with BD had reduced mean level of 
activation in the middle frontal gyrus compared to healthy relatives and unrelated controls (p <0.02); 
however relatives with MDD did not differ compared to any other group and had an intermediate 
level of mean activation between healthy relatives/ unrelated controls and BD patients.  In the 
superior temporal gyrus, BD patients showed a greater mean level of activation compared to healthy 
controls and psychiatrically well relatives (p<0.05); however, relatives with MDD did not differ 
compared to any group and had an intermediate level of mean activation between healthy 
relatives/controls and BD patients. In the posterior cingulate cortex, the mean level of activation was 
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reduced in relatives with MDD compared to all the other groups (p<0.04); all other pairwise 
comparisons were not significant. 
 
We examined the role of potential confounders in several ways. We used three multivariate analyses 
of variance with medication status (antiepileptics vs. not on antiepileptic, lithium vs. not on lithium 
and antipsychotic vs. not on antipsychotics) as the independent factors and levels of activation in 
suprathreshold clusters in patients with BD as dependent variables. No group differences were 
found (all P>0.28). We examined correlations between activation in suprathreshold regions in 
patients with BD and dose of lithium and antipsychotics on the day of scanning. None were 
significant (all r<0.21, P>0.28). Similarly, we did not observe any correlation with age of onset in 
patients and relatives with MDD (all r<0.23, P>0.07). Further analyses in the entire sample did not 
reveal significant correlations between the level of activation in any suprathreshold cluster and age 
(all r<0.10, P>0.27), IQ (all r<0.08, P>0.38), accuracy (all r<0.06, P>0.51) and response time (all 
r<0.16, P>0.08). None of these correlations survive correction for multiple testing.  
 
Multivariate Classification 
Patients with BD versus unrelated healthy controls: Classifiers using the 1-back or 2-back versus 0-
back contrast did not lead to a statistically significant differentiation between patients with BD and 
healthy controls. Classification based on the 1-back versus 0-back contrast resulted in 65.5% 
accuracy, 61. 5% sensitivity (true positives for BD) and 69.2% specificity (true negatives for unrelated 
controls) and was not significant (p=0.01).  Classification based on the 2-back versus 0-back contrast 
resulted in 73.1% accuracy, 76.9% sensitivity and 69.3% specificity and was also not significant 
(p=0.08).  In contrast, the classifier based on the 3-back versus 0-back contrast significantly 
differentiated patients from unrelated controls with an accuracy of 83.5% (p=0.001). The sensitivity 
of the classification was 84.6% and the specificity 92.3%/. The PPV (probability that individuals 
classified as BD patients were correctly identified) and NPV (probability that individuals classified as 
healthy controls were correctly identified) values were respectively 0.91 and 0.85. The 
unthresholded discrimination map showing the global spatial pattern by which the two groups differ 
based on the 3-back versus 0-back classifier is displayed in Figure 2A; the largest clusters 
discriminating patients with BD from unrelated controls were located in the left 
inferior/middle/superior frontal gyrus and in the superior parietal lobule. 
 
Patients with BD versus relatives with MDD: Significant results were found for classifiers based on 
contrast images from the 1-back (p=0.003), 2-back (p=0.001) and 3-back (p=0.001) conditions. The 
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classifier based on the 1-back versus 0-back contrast resulted in 76.9% accuracy, 53.9% sensitivity 
(true positives for patients with BD), 100% specificity (true negatives for relatives with MDD), PPV of 
1 and NPV of 0.68.  The classifier based on the 2-back versus 0-back contrast resulted in 73% 
accuracy, 61.5% sensitivity, 84.6% specificity, 0.79 PPV and 0.68 NPV. The classifier based on the 3-
back versus 0-back contrast resulted in 73.1% accuracy, 53.9% sensitivity, 94.5%specificity, 0.90 PPV 
and 0.67 NPV. To maintain consistency with the results of the other classification problems, the 
unthresholded discrimination map showing the global spatial pattern by which the two groups differ 
based on the 3-back versus 0-back classifier is displayed in Figure 2B; the largest discriminating 
clusters were located in the left superior frontal gyrus, right middle frontal gyrus, bilaterally in the 
middle /superior frontal gyrus and the right temporal lobe. 
 
Patients with BD versus healthy relatives: Classifiers using the 1-back or 2-back versus 0-back 
contrast did not differentiate between patients with BD and healthy relatives. Classification based on 
the 1-back versus 0-back contrast resulted in 54.5% accuracy, 36.6% sensitivity (true positives for 
patients with BD) and 72.3% specificity (true negatives for healthy relatives) but the results were not 
significant (p=0.41).  Classification based on the 2-back versus 0-back contrast resulted in 59.1% 
accuracy, 36.3% sensitivity and 81.2% specificity and was also not significant (p=0.17). In contrast, 
the classifier based on the 3-back versus 0-back contrast was significant (p=0.004) and had 81.8% 
accuracy, 72.7% sensitivity, 90.9% specificity (true for healthy relative), 0.88 PPV and NPV 0.76. The 
unthresholded discrimination map showing the global spatial pattern by which the two groups differ 
based on the 3-back versus 0-back classifier is displayed in Figure 2C; the largest discriminating 
clusters were located in the lingual gyrus and the cerebellum on the left. 
 
For each classifier, Pearson correlation analyses between GPC predictive probabilities and age, IQ, 
task accuracy and reaction time, age of onset, BPRS total score and medication dose were not 
significant (r<0.28; p>0.14).  
 
Discussion 
We demonstrate the potential translational utility of task-based fMRI in aiding diagnosis and 
prognosis in BD.  The approach highlighted here provides proof of concept for the development of 
new tools for the categorization of individuals where there is general agreement that clinical data 
alone are insufficient.   
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In this study we show that patients diagnosed with BD, show sufficient consistency in their 
neurofunctional patterns for them to be reliably differentiated from healthy individuals with an 
accuracy of 83.4%. Using structural MRI data alone, we have previously achieved classification 
accuracies of 69-78%  in differentiating patients with BD from healthy individuals based on whole-
brain  gray or white matter classifiers (Rocha-Rego et al., 2014). Others who have also used 
structural MRI data have reported similar or lower accuracies (Schnack et al., 2014). It would 
therefore appear that task-based fMRI data may improve classification accuracy in BD as they may 
be more sensitive to disease-related pathology. Additionally, it is encouraging that the clusters that 
contribute to the correct classification of patients compared to controls, show biological plausibility. 
The conventional fMRI analysis of this same dataset, as well as results from independent samples 
(Cremaschi et al., 2013; Fusar-Poli et al., 2012), have consistently identified decreased prefrontal 
activation in patients with BD in the 3-back vs 0-back contrast compared to healthy controls.  This is 
consistent with the clusters contributing to successful classification of patients from controls which 
implicate the prefrontal cortex, particularly lateral and frontopolar regions, and the dorsal parietal 
cortex, both key functional nodes of the working memory network (Niendam et al., 2012). 
Nevertheless, it could be argued that differentiating patients with established BD from healthy 
controls is of marginal clinical interest as real-life diagnostic assessments deal with more complex 
issues than separating people that have been ill for some time from those who are not ill at all 
(Wolfers et al., 2015). The value of testing classifiers for patients versus controls based on different 
imaging modalities is threefold. First, it serves to identify the type of data, or combinations of data, 
derived from neuroimaging applications that would be adapted for clinical practice. Once this is 
achieved, one could test the best-performing classifiers on different clinical groups that are 
prodromal or have atypical or comorbid presentations. Second, examining the relationship between 
the multivariate neuroimaging signature and the clinical or demographic features of a disorder can 
lead to mechanistic insights regarding etiology and progression.  Third, the availability of objective 
brain imaging tests can improve the social perception of psychiatry. At the level of individual 
patients, objective tests would provide re-assurance that clinical assessment and diagnostic 
assignment are not purely based on subjective judgment. At the societal level, it would help 
integrate psychiatry into mainstream medicine.  
 
To our knowledge this is the first study to employ neuroimaging to address core issues of clinical 
uncertainty. We provide preliminary evidence for using neuroimaging classifiers to differentiate 
MDD from BD, especially in individuals who have a family history of BD. There are several clinical 
indicators of increased likelihood of conversion to BD in those who present with depression and 
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have a family history of the disorder (Mitchell et al., 2008; 2011). However, none can be reliably 
applied to individual patients. In contrast, GPC classifiers differentiated patients with BD from 
relatives with MDD with an accuracy ranging from 73 to 77%. The sensitivity of these classifiers were 
low (53-62%). This is not surprizing given the phenomenological overlap between BD and MDD and 
the dominance of depressive psychopathology in both disorders (Judd et al., 2002; Forty et al., 
2009). What is more important however is that the classifier had very high specificity ranging from 
84-100%. In principle this means that at the level of the individual patient clinicians would be able to 
exclude the possibility of BD, with a very high level of confidence, after a 10-min brain scan.  This 
finding requires replication in different samples and settings and in more diverse clinical populations 
in terms of their age and duration of illness. Nevertheless, our results suggest that this is an avenue 
of research worth pursuing in demonstrating the translational value of neuroimaging.  
 
Our third classifier, based on the 3-back versus 0-back contrast, differentiated patients with BD from 
their psychiatrically healthy relatives with an accuracy of 81.8%. This classifier identified high-risk 
individuals unlikely to convert to BD with 90.9% specificity. However, its sensitivity was 72.7% which 
suggest that some high-risk individual likely to convent may be missed. These results are very 
encouraging and could potentially inform early intervention services, where positive family history is 
a key criterion of risk and possible service inclusion (Duffy et al., 2015). There are a number of 
behavioral indicators of increased likelihood of conversion to syndromal BD but longitudinal studies 
suggest that they have low predictive value as a significant number of high-risk individuals never 
convert (Tijssen et al., 2010). Correctly identifying those who are in need of treatment is of 
paramount significance both in terms of cost-effectiveness of early intervention services but also in 
terms of preventing unnecessary treatment, concern and self-stigmatization in those unlikely to 
convert to BD. Of the clusters contributing to the correct identification of healthy relative, one was 
in the lingual gyrus, an occipital region involved in visual processing, and another in the cerebellum. 
Intriguingly, the lingual gyrus is closely related to cognitive function particularly with increasing age 
in BD (Fears et al., 2014) and shows dysfunctional connectivity during a range of tasks in patients but 
not their unaffected relatives (Dima et al., 2013). The volume of the cerebellum has been shown to 
be increased in healthy relatives of patients (Kempton et al., 2009) compared to controls while in BD 
patients it is known to progressively decrease (Moorhead et al., 2007). Therefore clusters 
contributing to the correct categorization of healthy relatives may point us to regions that are 
particularly important for maintaining resilience when preserved or for disease expression when 
abnormal.  
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Patients with BD differed from the other groups (MDD relatives, healthy relatives, unrelated healthy 
individuals) in medication status. This raises the issue of whether classification might have been 
based on medication rather than diagnostic status. We cannot address this issue directly but we 
note that correlations between medication variables and GPC predictive probabilities were low and 
not statistically significant.  We have previously shown that medication status did not have a 
significant influence on classifier performance when using brain structural data to classify patients 
with BD from controls (Rocha-Rego et al., 2014). Patients with BD were on a variety of psychotropic 
agents with different mechanisms of action and it is therefore unlikely that the neural correlates of 
medication effects would be consistent across all participants. This mitigates the possibility that the 
classifiers could have identified uniform medication-related classification rules. In addition, the very 
low levels of psychopathology in patients suggest that it is unlikely that classification rules were 
derived from neural patterns associated with symptomatic expression on the day of the scan. 
Further investigations are, however, needed to confirm the reproducibility of our findings in more 
diverse and larger samples.  
 
In summary, this is the first study to our knowledge that has tested the contribution of neuroimaging 
to problems that arise in the clinical care of BD for which adequate non-imaging solutions have been 
elusive.  Although in need to replication and refinement, our data provide clear direction for the 
development of translational imaging applications in psychiatry.  
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Table 1. Demographic, Clinical and Task Performance Data 
 Unrelated  
Healthy 
Controls 
(n=30) 
Healthy 
Relatives 
 
(n=30) 
MDD 
Relatives 
 
(n=30) 
 
BD 
Patients 
 
(n=30) 
 
Age (years)  33.4 (11.6) 35.3 (5.6) 32.9 (9.9) 34.7 (7.7) 
Male: Female 15:15 14:16 16:14 15:15 
Full scale IQ  108.4 (10.9) 110.5 (10.5) 109 (11.4) 107.1 (12.1) 
Age of onset (years) 
 
n/a n/a 20.1 (9.1) 19.2 (10.8) 
HDRSa  0.1 (0.5) 0.1 (0.4) 1.3 (0.9) 3.2 (1.1) 
YMRSa  0.1 (0.8) (0) (0) 0.1 (1.3) 1.3 (0.7) 
BPRSa 24.4 (0.7) 24.5 (0.6) 25.4 (0.9) 27.1 (2.4) 
3-back, % correctb  73.2 (12.4) 88.5 (14.3) 73.4 (17.2) 69.8 (16.7) 
3-back, response time [sec]c 0.85 (0.3) 0.79 (0.3) 0.84 (0.5) 0.87 (0.6) 
Except for sex, data are presented as mean (standard deviation). Bipolar disorder=BD; BPRS=Brief Psychiatric Rating Scale; IQ= 
Intelligence Quotient;  HDRS=Hamilton depression Rating Scale; MDD=Major Depressive Disorder; YMRS=Young Mania Rating Scale; 
n/a=not applicable; there were no group differences in age, sex distribution, IQ and age of onset, P>0.7;  
 a Significant effect of group for HDRS, YMRS and BPRS P<0.001; Post-hoc pairwise Bonferroni corrected comparisons showed that 
patients with BD more symptomatic than all other groups, P<0.01; b  Significant effect of group F=15.8, P<0.01;  Post-hoc Bonferroni 
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Figure 1. Machine Learning Classification 
This is a simplified illustration of the Gaussian Process Classifier functions that outlines the general 
principles of multivariate machine learning classification as applied to neuroimaging data from two 
hypothetical groups, referred to as patient and comparison group. During the training phase (left 
panel), the classifier is separately presented with multiple neuroimaging datasets of individuals that 
belong to one or the other group. The algorithm uses these data to assign a predictive weight to 
each voxel as more or less likely to be associated with one or the other group. The output of the 
classifier is a discrimination maps showing regions that have the most significant contribution to 
classification (left panel, bottom left) and values regarding the performance of the classifier based 
on their separating hyperplane (left panel, bottom right). During the test phase, a previously unseen 
dataset is presented to the algorithm and is classified based on its probability of belonging to either 
the patient or comparison group.  
 
Figure 2. Unthresholded discrimination maps for the classifier based on the 3-back >0-back 
contrast: (A). Patients with Bipolar Disorder (BD) versus unrelated healthy individuals. In the 
corresponding discrimination map, positive coefficients (red) indicate clusters with predictive value 
for BD (B). Patients with BD versus relatives with Major Depressive Disorder. In the corresponding 
discrimination map, positive coefficients (red) indicate clusters with predictive value for BD (C). 
Patients with BD versus healthy relatives. In the corresponding discrimination map, positive 
coefficients (red) indicate clusters with predictive value for psychiatrically healthy relatives.    
 
 
 
corrected  pairwise comparisons showed healthy relatives outperformed all other groups, P<0.02;  Significant effect of group F=21.4, 
P<0.01;  Post-hoc Bonferroni corrected  pairwise comparisons showed healthy relatives outperformed all other groups, P<0.02 
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